featured
Continued 5-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and Risk of Reclassification and Adverse Pathological Outcomes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Journal of Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)
J Urol 2018 Aug 01;[EPub Ahead of Print], JT Kearns, AV Faino, JM Schenk, LF Newcomb, JD Brooks, PR Carroll, A Dash, WJ Ellis, M Fabrizio, ME Gleave, TM Morgan, PS Nelson, IM Thompson, A Wagner, Y Zheng, DW LinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.